{
    "2021-12-03": [
        [
            {
                "time": "2021-02-09",
                "original_text": "Eli Lilly's COVID-19 treatment now authorized high-risk patients 'of any age'",
                "features": {
                    "keywords": [
                        "Lilly",
                        "COVID-19",
                        "treatment",
                        "authorized",
                        "high-risk",
                        "patients"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-09",
                "original_text": "UPDATE 1-FDA clears use of Lilly's COVID-19 antibody therapy for kids",
                "features": {
                    "keywords": [
                        "FDA",
                        "clears",
                        "Lilly",
                        "COVID-19",
                        "antibody",
                        "therapy",
                        "kids"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-09",
                "original_text": "Lilly's COVID-19 antibody treatment authorized for young children and infants",
                "features": {
                    "keywords": [
                        "Lilly",
                        "COVID-19",
                        "antibody",
                        "treatment",
                        "authorized",
                        "young",
                        "children",
                        "infants"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-02-09",
                "original_text": "Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12",
                "features": {
                    "keywords": [
                        "Lilly",
                        "bamlanivimab",
                        "etesevimab",
                        "neutralizing",
                        "antibody",
                        "therapy",
                        "emergency",
                        "use",
                        "COVID-19",
                        "patients",
                        "under",
                        "age",
                        "12"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}